Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
100%(8 trials)

Phase Distribution

Ph phase_1
1
13%
Ph phase_4
1
13%
Ph phase_2
2
25%
Ph phase_3
4
50%

Phase Distribution

1

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
4(50.0%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 22 (25.0%)
Phase 34 (50.0%)
Phase 41 (12.5%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718509
completedphase_4

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

NCT00877487
completedphase_2

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

NCT00922272
completedphase_3

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149
completedphase_2

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

NCT00985725
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01718509Phase 3

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Completed
NCT00877487Phase 4

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

Completed
NCT00922272Phase 2

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Completed
NCT01436149Phase 3

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Completed
NCT00985725Phase 2

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Completed
NCT03260205Phase 3

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

Completed
NCT01718483Phase 3

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Completed
NCT01457339Phase 1

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8